Rezolute (RZLT) Other Operating Expenses (2011 - 2026)
Rezolute (RZLT) posted Other Operating Expenses of -$1.5 million for Q1 2026, up 69.79% sequentially from -$5.0 million in Q4 2025, and up 19.86% YoY from -$1.2 million in Q1 2025.
Rezolute (RZLT) Other Operating Expenses (2011 - 2026) Analysis & Trends
Rezolute has reported Other Operating Expenses for 12 years, with the latest figure at -$1.5 million in Q1 2026.
- Quarterly Other Operating Expenses rose 19.86% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.7 million (down 107.43% YoY) and the FY2025 annual result came in at -$7.6 million, down 32.43% from the prior year.
- Other Operating Expenses improved to -$1.5 million in Q1 2026 per RZLT's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$1.5 million in Q1 2026 and troughed at -$5.0 million in Q4 2025.
- A 3-year average of -$2.5 million and a median of -$1.9 million in 2024 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2025 and 2026: Other Operating Expenses sank 167.75% in 2025, then advanced 19.86% in 2026.
- Over 3 years, Other Operating Expenses stood at -$1.9 million in 2024, then slumped by 167.75% to -$5.0 million in 2025, then surged by 69.79% to -$1.5 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$1.5 million, -$5.0 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.50 Mn |
| Dec 31, 2025 | -4.96 Mn |
| Sep 30, 2025 | -3.32 Mn |
| Jun 30, 2025 | -1.96 Mn |
| Mar 31, 2025 | -1.87 Mn |
| Dec 31, 2024 | -1.85 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2019 | 180,000.00 |
| Mar 31, 2019 | 11,000.00 |
| Dec 31, 2018 | 145,000.00 |
| Sep 30, 2018 | 23,000.00 |
| Jun 30, 2017 | -291,202.00 |
| Mar 31, 2017 | -382,535.00 |
| Dec 31, 2016 | -301,520.00 |
| Sep 30, 2016 | -256,596.00 |
| Jun 30, 2016 | -203,277.00 |
| Mar 31, 2016 | -302,731.00 |
| Dec 31, 2015 | -198,466.00 |
| Sep 30, 2015 | -205,183.00 |
| Jun 30, 2015 | -191,870.00 |